USE OF HYBRID-CELLS IN IMMUNOTHERAPY

被引：3

作者：

FAVRE, R ^{[1
]}

CARCASSONNE, Y ^{[1
]}

MEYER, G ^{[1
]}

机构：

[1] INSERM,F-13009 MARSEILLE,FRANCE

来源：

ONCOLOGY | 1977年 / 34卷 / 02期

关键词：

D O I：

10.1159/000225190

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：84 / 86

页数：3

共 11 条

[1]

BONNEAU HP, 1971, MEM CES ANA PATH MAR

[2]

DULBECCO R, 1961, CANCER RES, V21, P975

[3]

FAVRE R, 1972, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences Serie D Sciences Naturelles, V275, P1835

[4]

FAVRE R, 1974, ANN IMMUNOL C, V105, P491

[5]

FAVRE R, 1974, BRIT J CANCER, V29, P30

[6]

FAVRE R, 1972, THESIS MARSEILLE

[7]

FISHER RA, 1957, STATISTICAL TABLES U

[8] SUPPRESSION OF MALIGNANCY BY CELL FUSION [J].

HARRIS, H ;

MILLER, OJ ;

KLEIN, G ;

WORST, P ;

TACHIBANA, T .

NATURE, 1969, 223 (5204) :363-+

[9] EXPRESSION OF POLYOMA-INDUCED ANTIGENS IN LOW MALIGNANT HYBRIDS DERIVED FROM FUSION OF A POLYOMA-INDUCED TUMOR WITH A FIBROBLAST LINE [J].

MEYER, G ;

BEREBBI, M ;

KLEIN, G .

NATURE, 1974, 249 (5452) :47-49

[10] TUMOR HYBRID CELLS - IMMUNOTHERAPEUTIC AGENT [J].

PARKMAN, R .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 52 (05) :1541-1545

← 1 2 →